Lucintel's latest market report analyzed that pharmaceutical contract manufacturing provides attractive opportunities in the big pharmaceutical, small & medium-sized pharmaceutical, and generic pharmaceutical markets. The pharmaceutical contract manufacturing market is expected to reach $222.0 billion by 2028 with a CAGR of 7.3%. In this market, biologics manufacturing is the largest segment by services, whereas big pharmaceutical is largest by end use industry.
Download Brochure of this report by clicking on https://www.lucintel.com/pharmaceutical-contract-manufacturing-market.aspx
Based on services, the pharmaceutical contract manufacturing market is segmented into manufacturing [API, FDF (parenteral, injectable, tablet, capsule, and oral liquid)], drug development, and biologics manufacturing. The biologics manufacturing segment accounted for the largest share of the market in 2023 and is expected to register the highest CAGR during the forecast period, due to increasing need for producing vaccines and biosimilars.
Browse in-depth TOC on “Pharmaceutical Contract Manufacturing Market”
100 – Figures/Tables
150 – Pages
The Pharmaceutical Contract Manufacturing Market is marked by the presence of several big and small players. Some of the prominent players offering pharmaceutical contract manufacturing include Thermo Fisher Scientific, Catalent, Lonza, Almac Group, Recipharm, Patheon, Grifols International, Dalton Pharma Services, and AbbVie.
Request Sample Report:
https://www.lucintel.com/pharmaceutical-contract-manufacturing-market.aspx
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link helpdesk@lucintel.com.